Halflytely is owned by Braintree.
Halflytely contains Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride.
Halflytely has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Halflytely are:
Halflytely was authorised for market use on 16 July, 2010.
Halflytely is available in for solution, tablet, delayed release;oral dosage forms.
Halflytely can be used as gastrointestinal lavage indicated for cleansing of the colon as a preparation for colonoscopy in adults.
The generics of Halflytely are possible to be released after 22 October, 2022.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7291324 | BRAINTREE | Method of bowel cleansing |
Oct, 2022
(5 months ago) |
Market Authorisation Date: 16 July, 2010
Treatment: Gastrointestinal lavage indicated for cleansing of the colon as a preparation for colonoscopy in adults
Dosage: FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL
2
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic